Abstract
Purpose: Safeguarding high-quality care using evidence-based radiation therapy for patients with head and neck cancer is crucial to improving oncologic outcomes, including survival and quality of life. Methods and Materials: The Veterans Administration (VA) National Radiation Oncology Program established the VA Radiation Oncology Quality Surveillance Program (VAROQS) to develop clinical quality measures (QM) in head and neck cancer. As part of the development of QM, the VA commissioned, along with the American Society for Radiation Oncology, a blue-ribbon panel comprising experts in head and neck cancer, to develop QM. Results: We describe the methods used to develop QM and the final consensus QM, as well as aspirational and surveillance QM, which capture all aspects of the continuum of patient care from initial patient work-up, radiation treatment planning and delivery, and follow-up care, as well as dose volume constraints. Conclusion: These QM are intended for use as part of ongoing quality surveillance for veterans receiving radiation therapy throughout the VA as well as outside the VA. They may also be used by the non-VA community as a basic measure of quality care for head and neck cancer patients receiving radiation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 409-423 |
| Number of pages | 15 |
| Journal | Practical Radiation Oncology |
| Volume | 12 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 1 2022 |
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
Fingerprint
Dive into the research topics of 'Consensus Quality Measures and Dose Constraints for Head and Neck Cancer with an emphasis on Oropharyngeal and Laryngeal Cancer from the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Practical Radiation Oncology, Vol. 12, No. 5, 01.09.2022, p. 409-423.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Consensus Quality Measures and Dose Constraints for Head and Neck Cancer with an emphasis on Oropharyngeal and Laryngeal Cancer from the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel
AU - Katsoulakis, Evangelia
AU - Kudner, Randi
AU - Chapman, Christina
AU - Park, John
AU - Puckett, Lindsay
AU - Solanki, Abhi
AU - Kapoor, Rishabh
AU - Hagan, Michael
AU - Kelly, Maria
AU - Palta, Jatinder
AU - Tishler, Roy
AU - Hitchcock, Ying
AU - Chera, Bhisham
AU - Feygelman, Vladimir
AU - Walker, Gary
AU - Sher, David
AU - Kujundzic, Ksenija
AU - Wilson, Emily
AU - Dawes, Samantha
AU - Yom, Sue S.
AU - Harrison, Louis
N1 - Funding Information: Sources of Support: Funding for this project was provided by the VA National Radiation Oncology Program to by the American Society for Radiation Oncology (ASTRO) for the development of consensus- and evidence-based clinical quality measures. The blue-ribbon panel was selected by ASTRO and were paid an honorarium for their participation from ASTRO from this funding source. The VA's National Radiation Oncology Program has a contract with Virginia Commonwealth University to provide medical physics services for some of the technical aspects of this work. Funding Information: Sources of Support: Funding for this project was provided by the VA National Radiation Oncology Program to by the American Society for Radiation Oncology (ASTRO) for the development of consensus- and evidence-based clinical quality measures. The blue-ribbon panel was selected by ASTRO and were paid an honorarium for their participation from ASTRO from this funding source. The VA's National Radiation Oncology Program has a contract with Virginia Commonwealth University to provide medical physics services for some of the technical aspects of this work. Disclosures: Dr Katsoulakis reports grants from NIH, Florida State Bankhead Coley, stocks Abbvie, Intuitive surgical, Pfizer, General Electric, Moderna, and Candel Therapeutics. Dr Chapman reports salary support from the VA National Radiation Oncology Program Office to support the work covered in the manuscript; grants from the National Cancer Institute; honorarium from ASCO Advantage Program; a 2-day lecture series to pharma; honorarium from NCCN Elevating Cancer Equity Working Group; honoraria for grand rounds lectures from Mayo Clinic, University of California, San Diego, University of Florida, Oregon Health and Science University, Virginia Chapter of the American College of Radiology; by the American Society for Radiation Oncology (ASTRO) registration covered for meeting faculty participation. Dr Chapman is also the post-graduate section officer of the National Medical Association. Dr Solanki reports salary support from the VA National Radiation Oncology Program Office to support the work covered in the manuscript; grant research funding from VA Office of Research & Development; consulting fees from Blue Earth Diagnostics; honorarium from ASCO Advantage Program; a 2-day lecture series to pharma; support for meetings ASTRO registration covered for meeting faculty participation; being a member of the board VA Precision Oncology Program for cancer of the prostate (POPCaP) PATCH advisory board, the VA Precision Oncology Program for cancer of the prostate (POPCaP) Localized Prostate Cancer advisory board, the American College of Radiology, CARROS council, and being the ASTRO multidisciplinary QA subcommittee co-chair. Dr Hagan reports receiving support for attending meetings and/or travel from the Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX. Dr Kelly reports travel expenses as speaker for annual meeting Oct. 2021 Association of VA Hematology/Oncology. Dr Palta reports being a member of the board of directors of the American Association of Physicists in Medicine. Dr Tishler reports serving on the Data Safety Monitoring Board Enzychem. Dr Chera, reports royalties or licenses from Naveris, INC, consulting fees ASTRO for participation in the blue ribbon panel, patents planned issued or pending ctHPVDNA, and stock or stock options from Naveris. Dr Feygelman reports a research grant from Varian Medical Systems, consulting fees from Viewray Inc, and support for meetings from Sun Nuclear Corp. Dr Walker reports honoraria for participation on head and neck blue ribbon panel. Dr Sher reports grants from Varian Medical Systems and up-to-date honorarium. Mrs. Kujundzic, Mrs. Wilson, and Dr Dawes report employment by ASTRO. ASTRO has a federal contract with the Department of Veterans Affairs. Dr Yom reports grants from Genentech, BioMimetix, Merck, EMD Serono, Bristol-Myers Squibb, and that their royalties from Springer are up-to-date. Funding Information: Disclosures: Dr Katsoulakis reports grants from NIH, Florida State Bankhead Coley, stocks Abbvie, Intuitive surgical, Pfizer, General Electric, Moderna, and Candel Therapeutics. Dr Chapman reports salary support from the VA National Radiation Oncology Program Office to support the work covered in the manuscript; grants from the National Cancer Institute; honorarium from ASCO Advantage Program; a 2-day lecture series to pharma; honorarium from NCCN Elevating Cancer Equity Working Group; honoraria for grand rounds lectures from Mayo Clinic, University of California, San Diego, University of Florida, Oregon Health and Science University, Virginia Chapter of the American College of Radiology; by the American Society for Radiation Oncology (ASTRO) registration covered for meeting faculty participation. Dr Chapman is also the post-graduate section officer of the National Medical Association. Dr Solanki reports salary support from the VA National Radiation Oncology Program Office to support the work covered in the manuscript; grant research funding from VA Office of Research & Development; consulting fees from Blue Earth Diagnostics; honorarium from ASCO Advantage Program; a 2-day lecture series to pharma; support for meetings ASTRO registration covered for meeting faculty participation; being a member of the board VA Precision Oncology Program for cancer of the prostate (POPCaP) PATCH advisory board, the VA Precision Oncology Program for cancer of the prostate (POPCaP) Localized Prostate Cancer advisory board, the American College of Radiology, CARROS council, and being the ASTRO multidisciplinary QA subcommittee co-chair. Dr Hagan reports receiving support for attending meetings and/or travel from the Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX. Dr Kelly reports travel expenses as speaker for annual meeting Oct. 2021 Association of VA Hematology/Oncology. Dr Palta reports being a member of the board of directors of the American Association of Physicists in Medicine. Dr Tishler reports serving on the Data Safety Monitoring Board Enzychem. Dr Chera, reports royalties or licenses from Naveris, INC, consulting fees ASTRO for participation in the blue ribbon panel, patents planned issued or pending ctHPVDNA, and stock or stock options from Naveris. Dr Feygelman reports a research grant from Varian Medical Systems, consulting fees from Viewray Inc, and support for meetings from Sun Nuclear Corp. Dr Walker reports honoraria for participation on head and neck blue ribbon panel. Dr Sher reports grants from Varian Medical Systems and up-to-date honorarium. Mrs. Kujundzic, Mrs. Wilson, and Dr Dawes report employment by ASTRO. ASTRO has a federal contract with the Department of Veterans Affairs. Dr Yom reports grants from Genentech, BioMimetix, Merck, EMD Serono, Bristol-Myers Squibb, and that their royalties from Springer are up-to-date. Publisher Copyright: © 2022
PY - 2022/9/1
Y1 - 2022/9/1
N2 - Purpose: Safeguarding high-quality care using evidence-based radiation therapy for patients with head and neck cancer is crucial to improving oncologic outcomes, including survival and quality of life. Methods and Materials: The Veterans Administration (VA) National Radiation Oncology Program established the VA Radiation Oncology Quality Surveillance Program (VAROQS) to develop clinical quality measures (QM) in head and neck cancer. As part of the development of QM, the VA commissioned, along with the American Society for Radiation Oncology, a blue-ribbon panel comprising experts in head and neck cancer, to develop QM. Results: We describe the methods used to develop QM and the final consensus QM, as well as aspirational and surveillance QM, which capture all aspects of the continuum of patient care from initial patient work-up, radiation treatment planning and delivery, and follow-up care, as well as dose volume constraints. Conclusion: These QM are intended for use as part of ongoing quality surveillance for veterans receiving radiation therapy throughout the VA as well as outside the VA. They may also be used by the non-VA community as a basic measure of quality care for head and neck cancer patients receiving radiation.
AB - Purpose: Safeguarding high-quality care using evidence-based radiation therapy for patients with head and neck cancer is crucial to improving oncologic outcomes, including survival and quality of life. Methods and Materials: The Veterans Administration (VA) National Radiation Oncology Program established the VA Radiation Oncology Quality Surveillance Program (VAROQS) to develop clinical quality measures (QM) in head and neck cancer. As part of the development of QM, the VA commissioned, along with the American Society for Radiation Oncology, a blue-ribbon panel comprising experts in head and neck cancer, to develop QM. Results: We describe the methods used to develop QM and the final consensus QM, as well as aspirational and surveillance QM, which capture all aspects of the continuum of patient care from initial patient work-up, radiation treatment planning and delivery, and follow-up care, as well as dose volume constraints. Conclusion: These QM are intended for use as part of ongoing quality surveillance for veterans receiving radiation therapy throughout the VA as well as outside the VA. They may also be used by the non-VA community as a basic measure of quality care for head and neck cancer patients receiving radiation.
UR - http://www.scopus.com/inward/record.url?scp=85136151157&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136151157&partnerID=8YFLogxK
U2 - 10.1016/j.prro.2022.05.009
DO - 10.1016/j.prro.2022.05.009
M3 - Article
C2 - 35667551
AN - SCOPUS:85136151157
SN - 1879-8500
VL - 12
SP - 409
EP - 423
JO - Practical Radiation Oncology
JF - Practical Radiation Oncology
IS - 5
ER -